Testing a new drug in people with liver disease
Part of Blood & lymphatic, Cancer, Digestive system, Immune system & allergy clinical trials.
This study looks at how a new oral drug (called INCB161734) is processed by the body and how safe it is in people with liver problems. It may help doctors understand the right dose for patients with liver impairment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have moderate or severe liver disease (called Child-Pugh class B or C).
- Your body mass index (BMI) must be between 18 and 44.
- You must be able to swallow and keep down oral tablets.
- You must not have had cancer (other than some skin cancers or very early breast/prostate cancer) in the last 5 years.
- You must not have a history of autoimmune disease (like myasthenia gravis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new experimental medicine (INCB123667) works and is tolerated in adults with moderate to severe liver problems. Researchers want to understand how the body processes this drug and whether it's safe in people with liver dysfunction.
This study tests an experimental drug called ulonivirine to see how the body processes it in people with mild or moderate liver problems compared to healthy volunteers. It helps doctors understand if the drug is safe and how it should be dosed for people with liver disease.
This trial tests a new medicine called eloralintide in people with healthy livers and in those with mild, moderate, or severe liver damage. It helps researchers learn how the liver affects the medicine in the body.
This study tests an experimental drug called INCB161734 in people with severe kidney disease or those on dialysis. It aims to see how the drug behaves in the body and if it is safe.
This is an early-stage study testing a new medicine called PF-08653944 in healthy adults and in people with varying degrees of liver function problems. The goal is to understand how the medicine works in the body and how liver function affects how the body processes it.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
Hear when a new Hepatic Insufficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.